Eli Lilly's Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly and Co (NYSE:LLY) 's acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target's lead assets remain in early clinical development, according to UBS analysts. The $3.25 billion deal, announced on Monday, is among the largest to date in the in vivo CAR-T space. UBS noted that interest in this emerging modality has been increasing across both oncology and autoimmune diseases, with Lilly already active in the area following its earlier acquisition of Orna Therapeutics. “This is an early-stage deal that we view as constructive and positive to continue to expand and diversify the pipeline for long-term growth beyond the GLP-1 franchise,” they wrote. Kelonia's lead program is a Phase I in vivo BCMA-targeted CAR-T therapy for multiple myeloma. UBS pointed to early clinical data presented in December 2025 showing that all four treated patients achieved minimal residual disease (MRD)-negative responses, with durabil
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly's US$7b Kelonia Deal Reshapes Oncology And Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly eyes Kelonia in $7B deal with $3.25B to be paid up front before investors could buy in. How to get in early [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Invests Weight-Loss Windfall in Next-Gen Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery [TheStreet.com]TheStreet.com
- Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade) [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website